• August 9, 2011

    OppNet is a trans-NIH initiative to expand the agency's funding of basic behavioral and social sciences research (b-BSSR). For more information and a link to funding announcements, please visit the OppNet web site.

  • August 9, 2011

    The NIH Common Fund supports the Science of Behavior Change program to improve our understanding of human behavior change across a broad range of health-related behaviors.

  • August 9, 2011

    The NIH Common Fund supports a health economics program to stimulate research of value for Health Care Reform.

  • December 6, 2011

    Investigators interested in using the Health and Retirement Study genotype data can find further information on the HRS website. Genotype and limited phenotype data will be available via the dbGaP application process. If investigators are interested in linking the genotype data with other HRS measures not in dbGaP they will be able to apply for access from HRS directly. A National Academy of Sciences Expert meeting was held to discuss the use of HRS GWA data.

  • April 21, 2010

    Rapamycin joins the aging fray: maybe Ponce de Leon visited Rapa Nui, not Florida. Sierra, F., J. Gerontol A Biol Sci Med Sci. 65:577-579, 2010.

  • February 19, 2009

    Biology of Aging Summit Report. Sierra, F., J Gerontol A Biol Sci Med Sci. 64:155-6, 2009.

    In September 2008, the Division of Aging Biology (DAB) of the National Institute on Aging (NIA) held a summit to assess the current state of research in the field of biogerontology and to attempt to delineate goals for the future. The 3-day meeting, held in Gaithersburg, Maryland, brought together a group of 40 well-respected scientists, from both within and outside the field, with sufficient expertise to address the global issues at hand. The main part of the meeting was a series of 15 sessions (with groups of three to four sessions in parallel), where rather than the usual presentation and discussion of data from individual speakers, free discussion of ideas was encouraged, partially driven by a set of questions chosen in advance by the session chairs and DAB. The subjects of discussion, as well as participants, were chosen by a steering committee chosen by DAB staff. The topics discussed are reflected in the accompanying articles in this issue of the Journals of Gerontology, which delineate the gaps and opportunities identified within various research areas, and summarize the collective conclusions reached by each of the discussion groups. As a way of introduction, it is relevant to indicate some (new) areas that came up repeatedly during the sessions and pervaded many of the discussions.



  • November 20, 2009

    The longevity dividend: why invest in basic aging research? Warner, H. and Sierra, F., Can J Aging. 28:391-398; (in French: 395-398), 2009.

  • January 1, 2011

    Acute kidney injury in older adults. Anderson S, Eldadah B, Halter JB, Hazzard WR, Himmelfarb J, Horne FM, Kimmel PL, Molitoris BA, Murthy M, O'Hare AM, Schmader KE, High KP. J Am Soc Nephrol. 22:28-38, 2011.

  • November 27, 2009

    Biomarker Validation for Aging: Lessons from mtDNA Heteroplasmy Analyses in Early Cancer Detection. P. E. Barker and M. Murthy. Biomarker Insights 4: 165–179, 2009.

  • April 15, 2010

    Workshop on Immunizations in Older Adults: Identifying Future Research Agendas. Kevin P.High, MD,MSc, Richard T.D’Aquila,MD, Rebecca A. Fuldner, PhD, Dale N. Gerding, MD, Jeffrey B. Halter, MD, Laura Haynes, PhD, William R. Hazzard, MD, Lisa A. Jackson, MD, Edward Janoff, MD, Myron J. Levin, MD, Susan G. Nayfield, MD, Kristin L. Nichol, MD, MPH, MBA, Mercy Prabhudas, PhD, Helen K. Talbot, MD, Charles P. Clayton,l Randi Henderson, Catherine M. Scott, Erika D. Tarver, Nancy F. Woolard, and Kenneth E. Schmader, MD. J Am Geriatr Soc 58: 765–776, 2010.

    Goals for immunization in older adults may differ from those in young adults and children, in whom complete prevention of disease is the objective. Often, reduced hospitalization and death but also averting exacerbation of underlying chronic illness, functional decline, and frailty are important goals in the older age group. Because of the effect of age on dendritic cell function, T cell-mediated immune suppression, reduced proliferative capacity of T cells, and other immune responses, the efficacy of vaccines often wanes with advanced age. This article summarizes the discussion and proceedings of a workshop organized by the Association of Specialty Professors, the Infectious Diseases Society of America, the American Geriatrics Society, the National Institute on Aging, and the National Institute of Allergy and Infectious Diseases. Leading researchers and clinicians in the fields of immunology, epidemiology, infectious diseases, geriatrics, and gerontology reviewed the current status of vaccines in older adults, identified knowledge gaps, and suggest priority areas for future research. The goal of the workshop was to identify what is known about immunizations (efficacy, effect, and current schedule) in older adults and to recommend priorities for future research. Investigation in the areas identified has the potential to enhance understanding of the immune process in aging individuals, inform vaccine development, and lead to more-effective strategies to reduce the risk of vaccine-preventable illness in older adults.